CliffBio
small molecule

DIVALPROEX SODIUM

DIVALPROEX SODIUM

Loss of exclusivity—loss of exclusivity
CompanyTeva →See this company's full patent-cliff portfolio

Drug detail

Brand nameDIVALPROEX SODIUM
Active ingredientDIVALPROEX SODIUM
StrengthEQ 125MG VALPROIC ACID
Dosage formCAPSULE, DELAYED REL PELLETS
RouteORAL
ModalitySmall molecule
FDA approvalNovember 2020
Marketing statusDISCN

More from Teva

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

DIVALPROEX SODIUM patent cliff — loss of exclusivity — | CliffBio